1Klein R. Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. Ⅱ. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol, 1984,102:520-526.
4Dahl-Jorgensen K, Hanssen KF, Brinchmann-Hansen O, et al.Near-normoglycemia retard the progression of early retinopathy and neuropathy in IDDM. Three year results from the Oslo Study. Diabetes, 1986,35:41A.
5Roy MS. Diabetic retinopathy in African Americans with type 1 diabetes: the New Jersey 725: Ⅱ. Risk factors. Arch Ophthalmal,2000, 118:105-115.
6Nielsen NV. Diabetic retinopathy: Ⅱ. The course of retinopathy in diabetics treated with oval hypoglycemic agents and diet regime alone:A one year epidemiologic cohort study of diabetes mellitus: The Island of Falster, Denmark. Acta Ophthalmol, 1984,62: 266-273.
7West KM, Erdreich HM, Stober JA.A detailed study of risk factors for retinopathy and nephropathy in diabetes. Diabetes, 1980,19:501-508.
8Knuiman MW, Welbom TA, McCann VJ, et al. Prevalence of diabetic complications in relation to risk factors. Diabetes, 1986,35:1332-1339.
2American Diabetes Association. Standards of medical care for patients with diabetes mellitus (position statement) [ J ]. Diabetes Care, 2003, 26(Suppl 1) : S33 - S50.
3Asian-Pactific Type 2 Diabetes Policy Group. Type 2 diabetes practical targets and treatments (Third edition)[C]. 2002.
4American Diabetes Association. Treatment of hypertension in adults with diabetes (position statement) [J]. Diabetes Care,2003, 26(Suppl 1): S83- S86.
5Brands MW, Fitzgerald SM, Hewitt WH, et al. Decreased cardiac output at the onset of diabetes: renal mechanisms and peripheral vasoconstriction. Am J Physiol Endocrinol Metab,2000, 278: 917.
6Zochodne DW, Verge VM, Cheng C, et al. Nitric oxide synthase activity and expression in experimental diabetic neuropathy. J Neuropathol Exp Neurol, 2000, 59: 798.
7Coppey LJ, Davidson EP, Dunlap JA, et al. Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res, 2000,1:131.
8Thomsen K, Rubin I, Lauritzen M, et al. NO-and non-NO-,non-prostanoid-dependent vasodilatation in rat sciatic nerve during maturation and developing experimental diabetic neuropathy. J Physiology, 2002, 543: 977.
9Karachalias N, Babaei-Jadidi R, Ahmed N,et al. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans, 2003, 31: 1423.
10Moore TC, Moore JE, Kaji Y,et al. The role of advanced gly cation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci, 2003, 44: 4457.
4Danesh J,Collins R,Peto R.Lipoprotein (a) and coronary heart disease.Meta-analysis of prospective studies.Circulation 2000,102 (10):1 082～1 085.
5Gazzaruso C,Garzaniti A,Falcone C,et al.Lipoprotein (a),apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in type 2 diabetic patients.J Diabetes Complications,2003,17 (3):135～140.
6High lipoprotein (a),diabetes,and the extent of symptomatic intracranial atherosclerosis.J.F.Arenillas,C.A.Molina,P.Chacon et al.NEUROLOGY,2004,63(2):27～32.
7Drexel H,Aczel S,Marte T,et al.Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care,2005,28 (1):101～107.
8Hladovec J,Rossman P. Circulating endothelial cells isolated to-gether with platelet and the experimental modification of their counts in rats. Thromb Res,1973,13(2):665-674.
9Dignat-George F,Sampol J. Circulating endothelial cells in vascula disorders: new insights into an old concept. Eur J Haematol,2000,65:215-220.
10Makin AJ, Blann AD,Chung NA, et al. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of cir-culating endothelial cells:Relationship with von Willebrand factor and tissue factor. Eur Heart J, 2004,25:371-376.
